Dr Marcela Maus retweeted
Clinical trial results from show "dramatic & rapid" regression of glioblastoma after next generation CAR T therapy at the @MGHCancerCenter with @MarcelaMaus, MD, director of the Cellular Immunotherapy Program. Learn more: spklr.io/6011Wf0l @NEJM
Dr Marcela Maus retweeted
Today, @NEJM published our clinical study of a novel #CARTCell in patients with #Glioblastoma. Early results with CARv3-TEAM-E suggest safety and bioactivity. Special thanks to all collaborators @MGHNeurosurg and @MGHCancerCenter!
nej.md/3VnjUIq
High antigen density of BCMA: friend or foe to CAR T cells? jitc.bmj.com/content/10/9/e0…
Dr Marcela Maus retweeted
Not all people respond equally well to CAR-T cell therapy, a kind of immunotherapy that has dramatically improved blood cancer treatment. A new single-cell study by researchers at the Broad, @MassGeneralNews, and @DanaFarber could help reveal why. broad.io/carttherapy0912
Dr Marcela Maus retweeted
A collaborative team at the @broadinstitute describes distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell #lymphoma.
🥼 @MarcelaMaus @gaddyg @Mark_Leick @Dr_KatieM @SatyenGohil
Learn more: go.nature.com/3eQtbWc
Dr Marcela Maus retweeted
.@MassGeneralNews researchers, led by ASGCT Board Member @MarcelaMaus & Associate Member @Mark_Leick, developed a novel treatment strategy that has the potential to bring the benefits of #CART #celltherapy to patients with acute myeloid #leukemia (#AML). https://teapawt.net/t.co/nLjH4x3bgB
Exciting new CAR design for AML from our lab! Now online @Cancer_Cell @MGHCancerCenter @MGBInnovation
Delighted to share our work optimizing CAR-T cells for acute myeloid leukemia. We're working rapidly on this devastating disease and will be presenting our dual targeting strategy building on this publication in May @ASGCT in Washington DC @Cancer_Cell cell.com/cancer-cell/fulltex…
Dr Marcela Maus retweeted
Delighted to share our work optimizing CAR-T cells for acute myeloid leukemia. We're working rapidly on this devastating disease and will be presenting our dual targeting strategy building on this publication in May @ASGCT in Washington DC @Cancer_Cell cell.com/cancer-cell/fulltex…
Dr Marcela Maus retweeted
Saw @Marcelamaus present this at #AACR2022 - really beautiful story! congrats.
Online at @nature: “CAR T cell killing requires the IFNγR pathway in solid but not liquid tumours” by @MarcelaMaus and colleagues nature.com/articles/s41586-0…
Dr Marcela Maus retweeted
How do CAR-T cells kill tumor cells? - It depends… Exciting work @Nature by @MarcelaMaus Rebecca Larson & colleagues on the role of IFNg signaling in CAR-T mediated killing. Congrats to the entire team! nature.com/articles/s41586-0…
Dr Marcela Maus retweeted
✨ New today in @Nature!
Dr. @MarcelaMaus at @harvardmed and colleagues demonstrated that liquid 💧 and solid 🧊 tumors differ in their interactions with #CAR T cells, particularly in regards to the IFNγR pathway.
go.nature.com/3xr4bfz
Dr Marcela Maus retweeted
Critical findings from a study @Nature led by @MarcelaMaus differentiating CAR T-cell efficacy against liquid versus solid tumors like #Glioblastoma ...INFg is the key!
nature.com/articles/s41586-0…
Dr Marcela Maus retweeted
Online at @nature: “CAR T cell killing requires the IFNγR pathway in solid but not liquid tumours” by @MarcelaMaus and colleagues nature.com/articles/s41586-0…
Dr Marcela Maus retweeted
Today #AACR22, don’t miss @njharlen presenting on single-cell analysis of cellular dynamics underlying clinical response to #CARTcell therapy in #collab work with Cathy Wu and @MarcelaMaus labs (Talk #3575). Then, read more of the story @medrxiv: medrxiv.org/content/10.1101/…
Dr Marcela Maus retweeted
Mechanisms of CAR T-cell therapy + #immunotherapy being discussed today at #AACR22 by @StBaldricks @SU2C #PediatricCancer Dream Team Co-leader Dr. Crystal Mackall + Innovative Rsch Grant Recipient @MarcelaMaus @MackallLab @StanfordCancer @MassGeneralNews
abstractsonline.com/pp8/#!/1…
Dr Marcela Maus retweeted
Excited to share the latest work from my PhD! We performed the first CRISPR activation screen to identify genes that drive solid tumor resistance to T cell-mediated cytotoxicity. A thread 1/X
nature.com/articles/s41467-0…
Dr Marcela Maus retweeted
Decades of studying the immune system's response to a virus help #researchers discover new treatments and potential cures to deadly diseases. Learn how this team at Mass General Brigham is working to change medicine. nyti.ms/3JX7iie
Dr Marcela Maus retweeted
Our 4th most downloaded article of 2021: Recent advances and discoveries in the mechanisms and functions of CAR T cells
by RC Larson & @MarcelaMaus
go.nature.com/2Y8lcbL
@harvardmed
#NRCtop10of2021
#Immunotherapy
Dr Marcela Maus retweeted
New #JITC short report: Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS) https://teapawt.net/t.co/VVFcgVtqGk @MJFzeta @MarcelaMaus
Dr Marcela Maus retweeted
ASGCT Board Member @MarcelaMaus MD, PhD, and colleagues at @MassGeneralNews demonstrated a novel approach that may reduce a serious adverse effect associated with #CART #celltherapy. https://teapawt.net/t.co/IRvgQqPIgR



























